ATE154641T1 - Neues physiologisch aktives schweinepeptid (cnp- 53) - Google Patents

Neues physiologisch aktives schweinepeptid (cnp- 53)

Info

Publication number
ATE154641T1
ATE154641T1 AT91111629T AT91111629T ATE154641T1 AT E154641 T1 ATE154641 T1 AT E154641T1 AT 91111629 T AT91111629 T AT 91111629T AT 91111629 T AT91111629 T AT 91111629T AT E154641 T1 ATE154641 T1 AT E154641T1
Authority
AT
Austria
Prior art keywords
peptide
cnp
swine
physiologically active
new physiologically
Prior art date
Application number
AT91111629T
Other languages
English (en)
Inventor
Hisayuki Matsuo
Kenji Kangawa
Naoto Minamino
Original Assignee
Hisayuki Matsuo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hisayuki Matsuo filed Critical Hisayuki Matsuo
Application granted granted Critical
Publication of ATE154641T1 publication Critical patent/ATE154641T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/58Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT91111629T 1990-07-13 1991-07-12 Neues physiologisch aktives schweinepeptid (cnp- 53) ATE154641T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2186582A JP2930380B2 (ja) 1990-07-13 1990-07-13 ブタ由来新規生理活性ペプチド(cnp―53)

Publications (1)

Publication Number Publication Date
ATE154641T1 true ATE154641T1 (de) 1997-07-15

Family

ID=16191066

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91111629T ATE154641T1 (de) 1990-07-13 1991-07-12 Neues physiologisch aktives schweinepeptid (cnp- 53)

Country Status (8)

Country Link
US (1) US5340920A (de)
EP (1) EP0466174B1 (de)
JP (1) JP2930380B2 (de)
AT (1) ATE154641T1 (de)
DE (1) DE69126568T2 (de)
DK (1) DK0466174T3 (de)
ES (1) ES2104635T3 (de)
GR (1) GR3024581T3 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1169573C (zh) 1998-09-28 2004-10-06 参天制药株式会社 用于治疗角结膜障碍的、包含作为活性组分的钠尿肽的泪液分泌促进剂或滴眼剂
BRPI0203172B8 (pt) 2001-09-28 2021-05-25 Nakao Kazuwa composição farmacêutica para acondroplasia
EP1759710B1 (de) * 2004-03-31 2014-05-07 Kazuwa Nakao Mittel zur behandlung oder prävention von arthritis
KR20070007842A (ko) 2004-03-31 2007-01-16 카즈와 나카오 신장증가용 조성물
ES2365023T3 (es) 2004-04-21 2011-09-20 Enobia Pharma Inc. Conjugados de administración ósea y método de uso de los mismos para dirigir proteínas a hueso.
TWI367213B (en) 2007-11-21 2012-07-01 Biomarin Pharm Inc Variants of c-type natriuretic peptide
EP2432489B1 (de) 2009-05-20 2016-10-05 BioMarin Pharmaceutical Inc. Varianten des natriuretischen peptids typ c
US9266939B2 (en) 2010-12-27 2016-02-23 Alexion Pharmaceuticals, Inc. Compositions comprising natriuretic peptides and methods of use thereof
SG11201401605QA (en) 2011-10-19 2014-09-26 Alexion Pharma Holding Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
RU2708068C2 (ru) 2014-12-05 2019-12-04 Алексион Фармасьютикалз, Инк. Лечение судорог с использованием рекомбинантной щелочной фосфатазы
CA2973883A1 (en) 2015-01-28 2016-08-04 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
US11352612B2 (en) 2015-08-17 2022-06-07 Alexion Pharmaceuticals, Inc. Manufacturing of alkaline phosphatases
EP3355904A4 (de) 2015-09-28 2019-06-12 Alexion Pharmaceuticals, Inc. Identifizierung wirksamer dosierungsschemata für gewebeunspezifische alkalische phosphatase-enzymersatztherapie von hypophosphatasie
EP3368062A4 (de) 2015-10-30 2019-07-03 Alexion Pharmaceuticals, Inc. Verfahren zur behandlung von craniosynostose bei einem patienten
SMT202600051T1 (it) 2016-01-08 2026-03-09 Ascendis Pharma Growth Disorders As Agonisti del cnp a rilascio controllato con effetti collaterali ridotti
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
WO2017173413A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Treating muscle weakness with alkaline phosphatases
WO2017173395A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
EP3464573B1 (de) 2016-06-06 2026-03-04 Alexion Pharmaceuticals, Inc. Auswirkungen von metallen auf die herstellung von alkalischen phosphatasen
US11116821B2 (en) 2016-08-18 2021-09-14 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
KR20240158374A (ko) 2017-03-31 2024-11-04 알렉시온 파마슈티칼스, 인코포레이티드 성인 및 청소년에서 저포스파타제증 (hpp)을 치료하는 방법
JP2021519590A (ja) 2018-03-30 2021-08-12 アレクシオン ファーマシューティカルズ, インコーポレイテッド 糖タンパク質の製造
JP7820148B2 (ja) 2018-08-10 2026-02-25 アレクシオン ファーマシューティカルズ, インコーポレイテッド アルカリホスファターゼを用いて神経線維腫症1型および関連状態を治療する方法
AU2020398898A1 (en) 2019-12-09 2022-07-21 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
US12083169B2 (en) 2021-02-12 2024-09-10 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2544929B2 (ja) * 1987-06-17 1996-10-16 第一化学薬品 株式会社 新規生理活性ペプチド
US5114923A (en) * 1988-05-31 1992-05-19 California Biotechnology Inc. Recombinant techniques for production of novel natriuretic and vasodilator peptides

Also Published As

Publication number Publication date
JP2930380B2 (ja) 1999-08-03
EP0466174B1 (de) 1997-06-18
DE69126568T2 (de) 1997-11-27
GR3024581T3 (en) 1997-12-31
DE69126568D1 (de) 1997-07-24
JPH0474198A (ja) 1992-03-09
ES2104635T3 (es) 1997-10-16
EP0466174A1 (de) 1992-01-15
US5340920A (en) 1994-08-23
DK0466174T3 (da) 1998-01-12

Similar Documents

Publication Publication Date Title
ATE154641T1 (de) Neues physiologisch aktives schweinepeptid (cnp- 53)
NO167295C (no) Fremgangsmaate for fremstilling av et terapeutisk aktivt peptid.
DK0475394T3 (da) Rotte C-type natriuretisk peptid cDNA, og precursorprotein
ATE241011T1 (de) Serin-reiche peptidlinker
DK1188768T3 (da) LHRH-antagonisk-peptider
SE8605189L (sv) Nya kalcitoninderivat
NO971621D0 (no) Keratinocyttvekstfaktoranaloger
BG97123A (bg) Производни на човешка, стимулирана от жлъчните соли, липаза и фармацевтични състави на тяхна основа
SE9603468D0 (sv) New compounds
SE7712634L (sv) Ny polypeptid med serumkalciumreducerande aktivitet
DK0490383T3 (da) Peptider af HIV-gag-proteinet, fremstilling og anvendelse deraf
AU2254588A (en) Biologically active segments of several growth hormones
SE9603461D0 (sv) New compounds
DE69126150D1 (de) Heparin bindender Wachstumsfaktor
DE68901361D1 (de) Anorexigenische und hypotensive peptide.
SE9603463D0 (sv) New compounds
SE9603462D0 (sv) New compounds
DK53290A (da) Syntetiske gaer-leader-peptider
EP0266006A3 (de) Blutdrucksenkende, diuretische Peptide

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee